Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosis

The farnesoid X receptor (FXR) agonist, a bile acid‐activated nuclear receptor, has been shown to improve the histologic features of nonalcoholic steatohepatitis (NASH); however, a satisfactory effect on hepatic fibrosis has not been achieved. We aimed to investigate the combined effect of FXR agoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Namisaki, Tadashi, Moriya, Kei, Kitade, Mitsuteru, Takeda, Kosuke, Kaji, Kosuke, Okura, Yasushi, Shimozato, Naotaka, Sato, Shinya, Nishimura, Norihisa, Seki, Kenichiro, Kawaratani, Hideto, Takaya, Hiroaki, Sawada, Yasuhiko, Akahane, Takemi, Saikawa, Soichiro, Nakanishi, Keisuke, Kubo, Takuya, Furukawa, Masanori, Noguchi, Ryuichi, Asada, Kiyoshi, Kitagawa, Koh, Ozutsumi, Takahiro, Tsuji, Yuki, Kaya, Daisuke, Fujinaga, Yukihisa, Yoshiji, Hitoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721465/
https://www.ncbi.nlm.nih.gov/pubmed/29404501
http://dx.doi.org/10.1002/hep4.1104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5721465/
https://www.ncbi.nlm.nih.gov/pubmed/29404501
http://dx.doi.org/10.1002/hep4.1104

Ejemplares similares